Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
imberje1
Tue, 04/09/2024 – 20:37
Read more about Novartis implements manufacturing adjustments for ribociclib to …
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
imberje1
Tue, 04/09/2024 – 20:37
Read more about Novartis implements manufacturing adjustments for ribociclib to …
Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
imberje1
Wed, 04/03/2024 – 14:36
Read more about Novartis confirms plans to file for Pluvicto® pre-taxane label …
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
imberje1
Mon, 01/08/2024 – 16:32
Read more about Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
PrintPDF